articleJournal of Clinical OncologyFeb 21, 2023HYBRID OA

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

MCMarina Chiara GarassinoSMShirish M. GadgeelGSGiovanna SperanzaEFEnriqueta FelipEEEmilio Esteban

University of Chicago · Fondazione IRCCS Istituto Nazionale dei Tumori · +19 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: NCT02578680 ). Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or…

Citation impact

617
total citations
FWCI
133.36
Percentile
100%
References
8
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Pemetrexed
  • Medicine
  • Pembrolizumab
  • Carboplatin
  • Internal medicine
  • Lung cancer
  • Oncology
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding